Despite four new launches in both the US and Canada in 2019, Teligent has reported turnover that fell by 5% to $16m in the fourth quarter. The company said that the decrease was driven primarily by “a decline in both US contract manufacturing and international injectable revenues, partially offset by a 24% increase in US Teligent-label topical revenues.”
However, on an annual basis sales in 2019 remained flat at $65.9m, “although the mix of where revenues originated changed...







